Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of Single Dose RO5313534 in Healthy Volunteers, and the Effect of RO5313534 on Safety and Tolerability of Steady State Memantine
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01196065
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1240
- Registration Number
- NCT01196780
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT01196078
A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT01195272
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Primary Progressive
- Interventions
- Other: Placebo
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 735
- Registration Number
- NCT01194570
- Locations
- 🇺🇸
Maxine Mesinger MS Clinic/Baylor College of Medicine; Neurology, Houston, Texas, United States
🇺🇸Swedish Neuroscience Institute; Multiple Sclerosis Center, Seattle, Washington, United States
🇺🇸MidAmerica Neuroscience Institute, Prairie Village, Kansas, United States
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: placebo to tocilizumab IVDrug: placebo to tocilizumab SCDrug: Disease-modifying antirheumatic drugs (DMARDs)
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2016-06-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1262
- Registration Number
- NCT01194414
An Observational Study on Long-Term Effectiveness and Safety of RoActemra/Actemra (Tocilizumab) in Daily Practice in Patients With Rheumatoid Arthritis (ICHIBAN)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3404
- Registration Number
- NCT01194401
A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
- Conditions
- Kidney Disease, Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 241
- Registration Number
- NCT01194154
- Locations
- 🇩🇪
Klinikum d.Universität München Campus Großhadern, München, Germany
🇩🇪Nierenzentrum Bogenhausen/Perlach; Praxis für Nierenheilkunde, München-Bogenhausen, Germany
🇩🇪Charité - Klinikum Mitte; Medizinische Klinik Für Nephrologie, Berlin, Germany
An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 289
- Registration Number
- NCT01194050
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 624
- Registration Number
- NCT01192906